Down-regulation of suppressor of cytokine signaling-3 causes prostate cancer cell death through activation of the extrinsic and intrinsic apoptosis pathways

Cancer Research

Volumn 69, Issue 18, 2009, Pages 7375-7384

  Puhr, Martin ^a   Santer, Frédéric R ^a   Neuwirt, Hannes ^a   Susani, Martin ^b   Nemeth, Jeffrey A ^d   Hobisch, Alfred ^e   Kenner, Lukas ^b,c   Culig, Zoran ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d CENTOCOR INC   (United States)

^e General Hospital Feldkirch   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 7; CASPASE 8; CASPASE 9; MESSENGER RNA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL 2; SMALL INTERFERING RNA; STAT1 PROTEIN; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; UPREGULATION;

APOPTOSIS; CASPASES; DOWN-REGULATION; ENZYME ACTIVATION; HUMANS; INTERLEUKIN-6; MALE; POLY(ADP-RIBOSE) POLYMERASES; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TRANSFECTION;

EID: 70349734599     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0806     Document Type: Article

References (49)

1. Hodge DR, Hurt EM, Farrar WL. The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 2005;41:2502-2512
2. Klein B, Tarte K, Jourdan M, et al. Survival and proliferation factors of normal and malignant plasma cells. Int J Hematol 2003;78:106-113 (Pubitemid 37021949)
3. Burke WM, Jin X, Lin HJ, et al. Inhibition of constitutively active Stat3 suppresses growth of human ovarian and breast cancer cells. Oncogene 2001;20:7925-7934 (Pubitemid 34002969)
4. Spiotto MT, Chung TD. STAT3 mediates IL-6-induced growth inhibition in the human prostate cancer cell line LNCaP. Prostate 2000;42:88-98. (Pubitemid 30056640)
5. Giri D, Ozen M, Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. Am J Pathol 2001;159:2159-2165 (Pubitemid 33104270)
6. Kamura T, Maenaka K, Kotoshiba S, et al. VHL-box and SOCS-box domains determine binding specificity for Cul2-Rbx1 and Cul5-Rbx2 modules of ubiquitin ligases. Genes Dev 2004;18:3055-3065 (Pubitemid 39658174)
7. Wong CP, Bray TM, Ho E. Induction of proinflammatory response in prostate cancer epithelial cells by activated macrophages. Cancer Lett 2009;276:38-46.
8. DeMarzo AM, Nelson WG, Isaacs WB, Epstein JI. Pathological and molecular aspects of prostate cancer. Lancet 2003;361:955-964 (Pubitemid 36332115)
9. Hammacher A, Thompson EW, Williams ED. Interleukin-6 is a potent inducer of S100P, which is up-regulated in androgen-refractory and metastatic prostate cancer. Int J Biochem Cell Biol 2005;37:442-450
10. Sasaki A, Yasukawa H, Suzuki A, et al. Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 1999;4:339-351 (Pubitemid 29359449)
11. Nicholson SE, De Souza D, Fabri LJ, et al. Suppressor of cytokine signaling-3 preferentially binds to the SHP-2-binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A 2000;97:6493-6498 (Pubitemid 30412741)
12. Kubo M, Hanada T, Yoshimura A. Suppressors of cytokine signaling and immunity. Nat Immunol 2003;4:1169-1176
13. Alexander WS, Hilton DJ. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu Rev Immunol 2004;22:503-529 (Pubitemid 38680432)
14. Larsen L, Ropke C. Suppressors of cytokine signalling: SOCS. APMIS 2002;110:833-844
15. Roberts AW, Robb L, Rakar S, et al. Placental defects and embryonic lethality in mice lacking suppressor of cytokine signaling 3. Proc Natl Acad Sci U S A 2001;98:9324-9329 (Pubitemid 32743915)
16. Takahashi Y, Carpino N, Cross JC, Torres M, Parganas E, Ihle JN. SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation. EMBO J 2003;22:372-384 (Pubitemid 36193583)
17. Marine JC, McKay C, Wang D, et al. SOCS3 is essential in the regulation of fetal liver erythropoiesis. Cell 1999;98:617-627 (Pubitemid 29418953)
18. He B, You L, Uematsu K, et al. SOCS-3 is frequently silenced by hypermethylation and suppresses cell growthin human lung cancer. Proc Natl Acad Sci U S A 2003;100:14133-14138 (Pubitemid 37499203)
19. Niwa Y, Kanda H, Shikauchi Y, et al. Methylation silencing of SOCS-3 promotes cell growth and migration by enhancing JAK/STAT and FAK signalings in human hepatocellular carcinoma. Oncogene 2005;24:6406-6417 (Pubitemid 41486474)
20. Weber A, Hengge UR, Bardenheuer W, et al. SOCS-3 is frequently methylated in head and neck squamous cell carcinoma and its precursor lesions and causes growth inhibition. Oncogene 2005;24:6699-6708 (Pubitemid 41486800)
21. Evans MK, Yu CR, Lohani A, et al. Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals. Oncogene 2007;26:1941-1948 (Pubitemid 46474639)
22. Bellezza I, Neuwirt H, Nemes C, et al. Suppressor of cytokine signaling-3 antagonizes cAMP effects on proliferation and apoptosis and is expressed in human prostate cancer. Am J Pathol 2006;169:2199-2208 (Pubitemid 351181978)
23. Neuwirt H, Puhr M, Cavarretta IT, Mitterberger M, Hobisch A, Culig Z. Suppressor of cytokine signalling-3 is up-regulated by androgen in prostate cancer cell lines and inhibits androgen-mediated proliferation and secretion. Endocr Relat Cancer 2007;14:1007-1019 (Pubitemid 351252432)
24. Hobisch A, Ramoner R, Fuchs D, et al. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Clin Cancer Res 2001;7:2941-2948 (Pubitemid 32911405)
25. Komyod W, Bohm M, Metze D, Heinrich PC, Behrmann I. Constitutive suppressor of cytokine signaling 3 expression confers a growth advantage to a human melanoma cell line. Mol Cancer Res 2007;5:271-281 (Pubitemid 46569778)
26. Savinainen KJ, Saramaki OR, Linja MJ, et al. Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol 2002;160:339-345
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254
28. Xie TX, Huang FJ, Aldape KD, et al. Activation of STAT3 in human melanoma promotes brain metastasis. Cancer Res 2006;66:3188-3196
29. Li WC, Ye SL, Sun RX, et al. Inhibition of growth and metastasis of human hepatocellular carcinoma by antisense oligonucleotide targeting signal transducer and activator of transcription 3. Clin Cancer Res 2006;12:7140-7148
30. Silver DL, Naora H, Liu J, Cheng W, Montell DJ. Activated signal transducer and activator of transcription (STAT) 3: localization in focal adhesions and function in ovarian cancer cell motility. Cancer Res 2004;64:3550-3558
31. Kusaba T, Nakayama T, Yamazumi K, et al. Expression of p-STAT3 in human colorectal adenocarcinoma and adenoma; correlation with clinicopathological factors. J Clin Pathol 2005;58:833-838 (Pubitemid 41113390)
32. Abdulghani J, Gu L, Dagvadorj A, et al. Stat3 promotes metastatic progression of prostate cancer. Am J Pathol 2008;172:1717-1728 (Pubitemid 351793362)
33. Kreis S, Munz GA, Haan S, Heinrich PC, Behrmann I. Cell density dependent increase of constitutive signal transducers and activators of transcription 3 activity in melanoma cells is mediated by Janus kinases. Mol Cancer Res 2007;5:1331-1341
34. Nakajima K, Yamanaka Y, Nakae K, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 1996;15:3651-3658 (Pubitemid 26239777)
35. Lu Y, Fukuyama S, Yoshida R, et al. Loss of SOCS3 gene expression converts STAT3 function from antiapoptotic to pro-apoptotic. J Biol Chem 2006;281:36683-36690 (Pubitemid 46042135)
36. Masuhiro Y, Kayama K, Fukushima A, et al. SOCS-3 inhibits E2F/DP-1 transcriptional activity and cell cycle progression via interaction with DP-1. J Biol Chem 2008;283:31575-31583
37. Krajewska M, Krajewski S, Epstein JI, et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 1996;148:1567-1576 (Pubitemid 26135897)
38. Krajewski S, Bodrug S, Krajewska M, et al. Immunohistochemical analysis of Mcl-1 protein in human tissues. Differential regulation of Mcl-1 and Bcl-2 protein production suggests a unique role for Mcl-1 in control of programmed cell death in vivo . Am J Pathol 1995;146:1309-1319
39. Colombel M, Symmans F, Gil S, et al. Detection of the apoptosis-suppressing oncoprotein bcl-2 in hormone-refractory human prostate cancers. Am J Pathol 1993;143:390-400. (Pubitemid 24058194)
40. Tu H, Jacobs SC, Borkowski A, Kyprianou N. Incidence of apoptosis and cell proliferation in prostate cancer: relationship with TGF-β1 and bcl-2 expression. Int J Cancer 1996;69:357-363 (Pubitemid 26384103)
41. Cavarretta IT, Neuwirt H, Untergasser G, et al. The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene 2007;26:2822-2832 (Pubitemid 46701444)
42. Isomoto H, Mott JL, Kobayashi S, et al. Sustained IL-6/STAT-3 signaling in cholangiocarcinoma cells due to SOCS-3 epigenetic silencing. Gastroenterology 2007;132:384-396 (Pubitemid 46108750)
43. Vanasse GJ, Winn RK, Rodov S, et al. Bcl-2 overexpression leads to increases in suppressor of cytokine signaling-3 expression in B cells and de novo follicular lymphoma. Mol Cancer Res 2004;2:620-631 (Pubitemid 39557665)
44. Rokhlin OW, Bishop GA, Hostager BS, et al. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57:1758-1768 (Pubitemid 27199671)
45. Steiner H, Cavarretta IT, Moser PL, et al. regulation of growthof prostate cancer cells selected in the presence of interleukin-6 antibody CNTO 328. Prostate 2006;66:1744-1752 (Pubitemid 44893900)
46. Sutherland KD, Vaillant F, Alexander WS, et al. cmyc as a mediator of accelerated apoptosis and involution in mammary glands lacking Socs3. EMBO J 2006;25:5805-5815 (Pubitemid 44967764)
47. Sutherland KD, Lindeman GJ, Visvader JE. Knocking off SOCS genes in the mammary gland. Cell Cycle 2007;6:799-803.
48. Sutherland KD, Lindeman GJ, Choong DY, et al. Differential hypermethylation of SOCS genes in ovarian and breast carcinomas. Oncogene 2004;23:7726-7733
49. Barclay JL, Anderson ST, Waters MJ, Curlewis JD. SOCS3 as a tumor suppressor in breast cancer cells, and its regulation by PRL. Int J Cancer 2008;124:1756-1766